Definium's LSD-Based Therapy Shows Strong Efficacy in Anxiety Disorder Trial
Event summary
- Definium's Phase 3 Voyage study of DT120 ODT in generalized anxiety disorder met primary endpoint, showing statistically significant improvement over placebo.
- LS mean change from baseline in HAM-A total score at Week 12 was -11.6 for DT120 vs. -6.2 for placebo (p<0.0001).
- DT120 ODT demonstrated rapid efficacy, with changes seen as early as Day 2 and sustained through Week 12.
- The study enrolled 214 participants across approximately 35 sites in the United States.
The big picture
Definium's positive Phase 3 results position DT120 ODT as a potential game-changer in the treatment of generalized anxiety disorder, an area with little innovation since the last FDA approval in 2007. The study's strong efficacy and rapid onset of action could redefine expectations for GAD treatments, addressing a significant unmet need in psychiatry. The upcoming Panorama topline results in September will further clarify DT120 ODT's potential as a transformative therapy.
What we're watching
- Regulatory Pathway
- Whether the FDA's Breakthrough Therapy designation will expedite approval for DT120 ODT in generalized anxiety disorder.
- Market Potential
- The pace at which Definium can scale commercialization if approved, given the 26 million U.S. adults affected by GAD.
- Competitive Landscape
- How Definium's results compare to other psychedelic-based therapies in development for mental health disorders.